ArticleAdvances in therapy2026
Cycling to TNFi vs. Switching to IL-17Ai Among Patients with Psoriatic Arthritis and Axial Spondyloarthritis: Real-World CorEvitas PsA/SpA Registry Data.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTumor necrosis factor inhibitors (TNFis) are a common first-line treatment option for patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA) with persistent disease activity despite conventional treatment. There is limited real-world evidence available to inform selection of therapy after first TNFi failure.
methodsThis study compares the effectiveness of cycling to a second TNFi versus switching to an interleukin-17A inhibitor (IL-17Ai) at 6-month follow-up, among patients with PsA and axSpA who discontinued a first TNFi. Patients were stratified into two groups: those who (1) initiated a second TNFi (cyclers) and (2) initiated an IL-17Ai (switchers). Inverse probability of treatment weighting (IPTW) was used to account for baseline differences between cyclers and switchers. Separate models were fit for the PsA and axSpA cohorts.
resultsThe PsA cohort included 277 (59%) cyclers and 194 (41%) switchers. Prior to IPTW, switchers demonstrated greater improvement (- 4.1 [95% confidence interval (CI) - 5.6, - 2.5]) in the primary outcome of change from baseline (CFB) in the Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA) versus cyclers. Post IPTW, switchers showed greater improvements across most secondary outcomes, and significantly greater improvements in Physician Global Assessment (PhGA) of arthritis and psoriasis (- 5.0 [95% CI - 9.3, - 0.8], p = 0.021) and non-work activity impairment (- 4.7 [95% CI - 9.2, - 0.2], p = 0.039). The axSpA cohort included 119 (69%) cyclers and 53 (31%) switchers. Prior to IPTW, switchers demonstrated greater improvement (- 0.7 [95% CI - 1.2, - 0.2]) in the primary outcome of CFB in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) versus cyclers. Post IPTW, switchers showed significantly greater improvement in patient fatigue (- 9.4 [95% CI - 15.8, - 3.1], p = 0.004) and numerically greater improvements across remaining secondary outcomes.
conclusionSwitching to IL-17Ai vs. cycling to another TNFi provided similar or numerically improved outcomes in both cohorts, underscoring the importance of considering alternative mechanisms of action for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.